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Abstract 
The STroke Imaging Research (STIR) group, the Imaging Working Group of StrokeNet, the 
American Society of Neuroradiology and the Foundation of the American Society of Neuroradiology 
sponsored an imaging session and workshop during the Stroke Treatment Academy Industry 
Roundtable (STAIR) IX on October 5-6, 2015 in Washington, D.C. This forum brought together 
stroke neurologists, neuroradiologists, neuroimaging research scientists, members of the National 
Institute of Neurological Disorders and Stroke (NINDS), industry representatives, and members of 
the U.S. Food and Drug Administration (FDA) to discuss stroke imaging research priorities in the 
light of an unprecedented series of positive acute stroke endovascular therapy clinical trials. The 
imaging session summarized and compared the imaging components of the recent positive 
endovascular trials, and proposed opportunities for pooled analyses. The imaging workshop 
developed consensus recommendations for optimal imaging methods for the acquisition and analysis 
of core, mismatch and collaterals across multiple modalities, and also a standardized approach for 
measuring the final infarct volume in prospective clinical trials. This article reports on neuroimaging 
biomarkers for treatment selection and for outcome in the context of clinical research. 
 
Introduction 
Over the prior two decades, an accumulated body of evidence from the stroke research community 
has led to incremental advances in the standardization of clinical trial methodologies and to the 
emergence of a central role for imaging in new treatment evaluations. The recent series of positive 
endovascular trials owe much of their success to the lessons learned from the many prior trials that 
failed to establish therapeutic efficacy.1-5 These prior stroke trials have led to an understanding of the 
roles of vascular, core, penumbral, and collateral imaging and their relationships to treatment 
response and clinical outcome. The goal of this article is to report on neuroimaging biomarkers for 
treatment selection and for outcome. 
It is beyond question that time from onset of focal cerebral ischemia to reperfusion is fundamental in 
determining therapeutic efficacy for reperfusion therapies.6 The effect of early treatment of stroke 
with intravenous alteplase demonstrated in the hallmark NINDS trial7 illustrates this principle; a 
robust and reliable benefit compared to placebo is related to time from onset to treatment.8 
However, when time and brain imaging by standard non-contrast CT (NCCT) imaging are 
insufficient to accurately test a therapeutic hypothesis, selection based on imaging of a biological 
target for treatment is a logical alternative (Table 1). Examples may be clinical trials in which the 
anticipated effect size is small (e.g., comparing two lytic medications or testing of a neuroprotective 
drug) or in which the treatment is relevant only for a subset of stroke types (e.g., large vessel 
occlusion). The STIR consortium has recommended the term TRAIT (Treatment-Related Acute 
Imaging Target) to describe patient selection based upon the biologic target of a treatment. The 
responses of these biologic targets to treatment may depend on time.9 The series of positive 
endovascular trials confirmed the value of TRAIT selection and enrichment for endovascular 
reperfusion strategies (Table 1). The trials demonstrated that patient recruitment limited to an 
imaging defined subset of stroke led to positive trials with smaller samples completed within 
reasonable periods of time. EXTEND IA illustrates how a greater enrichment results into a smaller 
sample and greater effect size, but potentially also decreased generalizability and excluded patients 
who may have benefited from treatment. 
 
Imaging Selection in Recent Positive Acute Stroke Endovascular Clinical Trials 
After three neutral endovascular trials in 2013 (IMS III, MR RESCUE and SYNTHESIS)10-13, the 
years 2014-2015 were marked by a historic series of positive acute stroke clinical trials (Table 2). The 
use of advanced imaging-based selection for patient recruitment in these recent trials is one of the 
most important factors in the success of these trials (Table 3). The imaging modalities required for 
each trial were different (Table 4). There is no evidence that the different imaging modalities resulted 
in different times from symptom onset to treatment (Table 5). 
In the MR CLEAN trial1, the key imaging findings included a clear benefit of endovascular therapy 
for NCCT ASPECTS scores of 5-10, and a post-hoc analysis demonstrated that a good and 
moderate collateral score was also associated with a large benefit of endovascular therapy. On the 
other hand, while Perfusion CT (PCT) mismatch (CBV and MTT thresholds) predicted functional 
outcome, the relative treatment effect in patients with and without mismatch was similar. The use of 
an ischemic core volume >70mL on PCT criterion did identify a group of patients with very low 
rates of independent outcome (1/13 (8%) endovascular treated patients achieved mRS 0-2) but there 
were relatively few patients and the interaction test was not significant.14 
The EXTEND IA trial2 showed a robust effect of endovascular therapy over alteplase alone in 
patients with PCT-defined mismatch and core volume <70mL. In this group of patients, near 
complete reperfusion (>90%) in target mismatch patients was strongly tied to favorable clinical 
outcome (regardless of the treatment strategy) and lack of reperfusion was associated with death or 
dependence in 70% of patients. 
In the ESCAPE trial3, an imaging strategy of NCCT ASPECTS scores of 6-10, as well as good and 
moderate collateral scores on CT Angiography (CTA), showed a robust effect favoring endovascular 
therapy. ASPECTS and collateral scores were highly correlated. Patients with higher clot burden 
assessed using the clot burden score demonstrated more treatment effect. 
In the SWIFT PRIME trial4, a target mismatch based on perfusion imaging combined with successful 
recanalization was associated with a favorable outcome. Final infarct volume strongly correlated with 
clinical outcome in both treatment groups. Baseline ischemic core volume predicted 27-hour infarct 
volume in patients who reperfused. In target mismatch patients, the combination of baseline core 
and 27-hour hypoperfusion volume predicted final infarct volume. 
The REVASCAT trial5 supported NCCT-based patient selection, only requiring ASPECTS of 6 or 
greater, demonstrating a robust treatment effect. However, significant discrepancies were observed 
between the centralized core lab ASPECTS and the investigators’ ASPECTS, and some benefit with 
lower ASPECTS scores (0-4) cannot be excluded. A pooled analysis of all patients with ASPECTS 0-
4 across all endovascular trials is needed, but may be too small to draw reliable conclusions regarding 
endovascular treatment effects. Interestingly, there were also significant discrepancies between M1 
versus M2 occlusions between the core lab and the investigators. It is important to note that, if the 
inclusion criteria were expanded to fully embrace the actual recruited subjects (e.g. lower ASPECTS 
to 3-10 range) that a similar cohort would be enrolled and still show benefit. 
THERAPY (ClinicalTrials.gov Identifier: NCT01429350), which required hyperdense clot length 
measurement ≥8mm on NCCT for trial inclusion, suggested that the benefit of bridging 
endovascular therapy relative to IV thrombolysis alone increased with hyperdense clot length, and 
large infarcts as measured by final NCCT ASPECTS 0-4 to be associated with very poor outcome 
providing further support for this threshold as a useful treatment exclusion criterion. 
The THRACE study (ClinicalTrials.gov Identifier: NCT01062698) has not been published to date. 
This study required demonstration of an arterial occlusion but similar to MR CLEAN, did not utilize 
NCCT or other criteria to exclude patients with a large ischemic core. 
Opportunities for Standardization 
While the above listed stroke clinical trials had several elements in common (occlusion location, 
ischemic core size), they also had significant differences, which represents a unique opportunity for 
standardization. More specifically, the scoring systems used to characterize ischemic core and 
collateral circulation varied from trial to trial. The pooling of the imaging data from these trials offers 
great opportunities to refine the imaging selection of patients for acute reperfusion therapy and trials 
(last column in Table 4). A statistical analysis plan for the pooled analysis of all the endovascular trials 
have been published15, which will focus on ASPECTS, M1 versus other arterial occlusion sites, and 
good/moderate versus poor collaterals. The optimal set of imaging biomarkers to select acute stroke 
patients may vary depending on the revascularization therapy being considered, the population being 
studied, and the time window under investigation, in agreement with the concept of TRAITs defined 
in STIR Roadmap II16. Imaging remains essential for phase II trials, and more than one imaging 
method is probably acceptable for patient selection purposes, as long as reasonable cross-modality 
concordance and within modality standardization and reliability are achieved. The STAIR/STIR 
imaging workshop recommends imaging based selection for acute stroke reperfusion clinical trials 
(not limited to endovascular therapies) as outlined in Table 1.  
The specific imaging methods proposed for patient selection using each TRAIT are outlined in Table 
1. Table 1 contains the acceptable options for patient selection in clinical trials and are not listed in 
any order of priority . 
Exclusion of patients with large ischemic core was a feature of most of the recent positive acute stroke 
clinical trials. Since the interaction of treatment with this imaging variable cannot be determined 
reliably due to the very small numbers of subjects across all trials, neither safety nor efficacy of 
reperfusion therapies in this group is established. Future studies investigating the sensitivity and 
specificity of each method/modality used to define ischemic core is essential.17,18 Furthermore, 
studies investigating the relationship between the ischemic core volume and collaterals19 should be 
pursued. The definitions of ischemic core will need to be revisited in populations of patients with 
ultra-fast reperfusion. The geographic distribution of the ischemic core may need to be considered in 
addition to its volume to reflect the eloquence of the infarcted region. Finally, future studies will need 
to determine whether treatment of patients with larger ischemic cores is associated with higher rates 
of symptomatic intracranial hemorrhage when treated. The research priorities for core and the other 
TRAITs are outlined in Table 6. 
Standardization of the grading of collateral circulation on and between CT and MRI are needed. The 
importance of collateral circulation must also be more robustly validated in prospective acute 
ischemic stroke. Future studies comparing single-phase and multiphase CTA for this purpose, are 
warranted, considering that a dichotomous definition of collaterals (absent/poor versus 
good/moderate) is probably sufficient. 
Perfusion derived entities, such as the core and penumbra, are the imaging biomarkers that will require 
the largest effort in terms of standardization considering the number of existing definitions and the 
difference between imaging modalities. There are now data sets available to benchmark and compare 
processing of acute PCT against a concurrent DWI scan.18 Also, much of the previous work to 
define optimal thresholding did not involve patients with ultra early reperfusion, and repeat work 
should be undertaken using the imaging data collected in these patients. 
These efforts to refine and standardize imaging selection must also inform the concept of futility in 
stroke reperfusion therapy. A futile imaging profile should identify groups of patients in whom a 
therapy offers little to no clinical benefit particularly if there is increased risk of harm. A futile profile 
will depend on a number of considerations, including time from onset window, anatomic location of 
existing core infarction, type of treatment, and other clinical variables, such as patient age, NIHSS 
score, and patient preferences.20 One commonly used definition of unfavourable outcome, mRS 3-6, 
ignores potentially meaningful shifts from severe to moderate disability. The dichotomous approach 
has been modified to classify mRS 4-6 as poor clinical outcome (e.g. hemicraniectomy for space 
occupying cerebral edema). However an ordinal analysis approach using the full scale of the mRS to 
generate numbers needed to treat (NNT) to achieve an improvement of at least 1 level on the mRS 
(perhaps combining 5 and 6 if that transition is not deemed meaningful) is an alternative approach 
that avoids arbitrary dichotomies. Similarly, patient-oriented outcomes, such as the NeuroQol or 
PROMIS, may also be considered. Recent small studies have shown that they correlate well with the 
mRS but have greater capacity to discriminate smaller but still meaningful change.21,22 In order to 
address the issue of futility, future research efforts should include using pooled analysis of data from 
recent trials as well as large imaging based observational studies that enroll either patients without the 
TRAITs or all comers with a subsequent analysis of outcome by imaging profile to derive futility 
thresholds for current reperfusion therapy.23 
Two ongoing trials, PRACTISE (ClinicalTrials.gov Identifier: NCT02360670) and PISTE-2, have 
been designed to better understand imaging selection strategy and the impact on treatment, rather 
than to test a specific treatment. PRACTISE is currently testing CT-based advanced imaging 
selection in IV thrombolysis decisions. PISTE-2 will have two arms, one with advanced imaging and 
one without advanced imaging selection and it is hoped that these will provide information on the 
added value of advanced imaging. 
 
Final infarct volume 
Final infarct volume (FIV) can potentially be a useful biomarker in phase II trials to provide an early 
signal of efficacy for a new treatment. The rationale is that FIV is a more direct measurement for 
biological effect compared to clinical outcome which depends heavily on infarct location and can be 
affected by unrelated pathology. However, it is not clear that FIV is an equivalent or more powerful 
measure of treatment effect than clinical measures of outcome.  This is an important research 
question that has been addressed in earlier treatment trials of t-PA (imaging outcomes less powerful 
than clinical outcome measures to detect treatment effect with t-PA) but has yet to be investigated in 
the current endovascular trials.   What is clear is that all FIV imaging approaches are known to 
correlate with long-term clinical outcome. However, what matters is not the degree of correlation but 
rather the ability to properly classify patients to predict accurately the long-term outcome. Also, the 
best approach and timing for measuring FIV requires further investigation. Measuring FIV early after 
stroke treatment (within 24 to 48 hours) has the advantage that the majority of patients remain in 
hospital, but the disadvantages that the lesion volume and signal intensity may still be changing or 
may be confounded by edema and by parenchymal hematomas. Early mortality at this time point is 
uncommon and becomes increasingly problematic with later imaging endpoints as it inevitably leads 
to missing data in a biased manner. Measuring FIV later (30-90 days) has the advantage of a more 
stable true final lesion, but the patient is less likely to be available for follow-up scan, tissue atrophy 
may underestimate the infarct volume, and distinguishing the index infarct from chronic ischemic 
damage may be impossible, or at least subjective. At all time points lesion detection and contrast is 
superior for MRI than CT, making it the preferred modality for final lesion volume measurement. 
However, CT may be required when MRI is contraindicated or unavailable. The recommended MRI 
sequence to determine the FIV is diffusion-weighted imaging (DWI) at 24-48 hours.24 Performing 
DWI earlier than 24 hours risks underestimating lesion volume due to temporary post-reperfusion 
reversal.25 MRI with FLAIR imaging performed at 3-5 days or just before discharge is an alternative 
approach that reduces the potential risk of late infarct growth occurring in non-reperfused patients 
whilst minimizing loss to follow-up.26 However, differentiating the acute lesion from chronic 
ischemia can be more challenging and edema is prominent at this time. The optimal timing for CT 
follow up (when MRI is not available) needs further investigation (i.e., 24-72 hours versus 3-5 days). 
Research on confounding factors including edema, hemorrhagic transformation, contrast staining on 
CT, fogging, etc. are necessary to increase validity of the use of final infarct volume as a biomarker. 
Adjustment to account for the anatomical location and distribution of the final infarct relevant to 
clinical outcome whether it affects eloquent regions or not, would clearly be relevant to models 
aiming to predict functional outcome. However, for assessment of biological treatment effect, 
removal of this potential confound is a benefit rather than a pitfall.  
The research priorities for final infarct volume are outlined in Table 6. 
 
  
Imaging Technology Issues 
Imaging selection for acute stroke could benefit from several technological improvements that would 
ensure that the requirement for speed does not result in reduced use of advanced imaging which 
could impair future pathophysiologic insights and treatment advances.  
MRI use could become more widespread with recent advances in rapid stroke imaging protocols but 
would require an effective fast safety screening process. The risk associated with the administration 
of gadolinium needs to be addressed, and alternative approaches to assess perfusion such as arterial 
spin labeling need to be further evaluated. 
NCCT could benefit from a focus on improving image acquisition quality and workflow that would 
improve core detection, including characterization of ASPECTS score. A focus on standardizing 
optimal acquisition techniques would be helpful, and should consider a wide range of CT 
technologies available, including the emerging availability of mobile stroke units. 
PCT would benefit greatly from increased signal contrast to noise through improved software and 
perhaps contrast agent approaches. Faster image reconstruction, transfer and processing are critical, 
not just to produce standardized maps but to rapidly generate dynamic angiography. Minimum 
hardware requirements such as ability to operate at low kilovoltage of 80 kV (or 70kV when 
available), volumetric coverage, and safety dose-check features should be considered. 
Rapid technological advances could open new horizons in terms of imaging selection of acute stroke 
patients for treatment. 
 
Conclusion 
Recent positive acute stroke endovascular clinical trials have demonstrated the added value of 
neurovascular imaging. The optimal imaging profile for endovascular treatment includes large vessel 
occlusion, smaller core, good collaterals and large penumbra. However, equivalent definitions for the 
imaging profile parameters across modalities are needed, and a standardization effort is warranted, 
potentially leveraging the pooled data resulting from the recent positive endovascular trials. 
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Tables 
 
Table 1. Imaging Recommendations 
Baseline imaging markers that favor treatment response of thrombectomy 
Treatment-Related Acute Imaging Target (TRAIT) for thrombectomy 
• Large artery of occlusion 
• Small core 
• Large core-perfusion mismatch (penumbral marker) 
• Good cerebral collaterals 
Imaging selection of patients for acute reperfusion trials (not limited to endovascular 
therapies): Recommendations 
• Imaging for defining the Treatment Relevant Acute Imaging Target (TRAIT) is highly recommended for 
patient selection 
• Additional time spent acquiring additional imaging information must be balanced against risk of delay in 
initiating reperfusion therapies 
• Pre-randomization vascular imaging should be obtained in acute endovascular trials. This would usually 
be done by CTA or MRA 
• Vascular, core, mismatch and collateral imaging each have added value for identifying TRAIT and 
enriching sample toward greatest effect size. More than one imaging method and threshold criterion is 
acceptable for these purposes, but should be standardized within a trial 
• Particularly in phase II trials with small sample sizes, both vascular and advanced tissue imaging may offer 
insights into patient populations that cannot be obtained from clinical data alone, and are recommended 
to assist characterization of patient populations and improve understanding of experimental therapies 
Proposed imaging methods for patient selection 
TRAIT Proposed imaging methods 
Artery occlusion • CTA 
• MRA 
• Catheter angiography 
Core • ASPECTS on NCCT 
• Volume of severely decreased CBV or CBF from PCT 
• Volume of acute DWI lesion from MRI 
Mismatch • Volume of perfusion lesion (by PCT, MRP or ASL) to core volume 
Cerebral collaterals • CTA source images 
• Single- or multiphasic CTA 
• Contrast-enhanced MRA 
• Catheter angiography 
 
 
Table 2. Imaging characteristics in medical treatment and endovascular treatment groups of recent positive acute stroke clinical trials 
 MR CLEAN EXTEND-IA ESCAPE SWIFT PRIME REVASCAT THERAPY 
 Medical 
treatmen
t (n=267) 
Endovas
cular 
treatmen
t (n=233) 
Medical 
treatmen
t (n=35) 
Endovas
cular 
treatmen
t (n=35) 
Medical 
treatmen
t (n=150) 
Endovas
cular 
treatmen
t (n=165) 
Medical 
treatmen
t (n=98) 
Endovas
cular 
treatmen
t (n=98) 
Medical 
Treatme
nt 
(n=103) 
Endovas
cular 
Treatme
nt 
(n=103) 
Medical 
treatmen
t (n=53) 
Endovas
cular 
treatmen
t (n=55) 
Site of 
vessel 
occlusion 
            
ICA 80/266 
(30%) 
61/233 
(26.1%) 
11/35 
(31.4%) 
11/35 
(31.4%) 
42/150 
(28%) 
48/165 
(29.1%) 
15/94 
(16%) 
17/93 
(18.3%) 
41/103 
(39.8%) 
45/103 
(43.7%) 
12/53 
(22.6%) 
18/55 
(32.7%) 
M1 165/266 
(62%) 
154/233 
(66.1%) 
18/35 
(51.4%) 
20/35 
(57.2%) 
103/150 
(68.7%) 
111/165 
(67.3%) 
72/94 
(76.6%) 
62/93 
(66.7%) 
65/103 
(63.1%) 
66/103 
(64.1%) 
36/53 
(67.9%) 
31/55 
(56.4%) 
M2 21/266 
(8%) 
18/233 
(7.8%) 
6/35 
(17.2%) 
4/35 
(11.4%) 
5/150 
(3.3%) 
6/165 
(3.6%) 
6/94 
(6.4%) 
13/93 
(14%) 
8/103 
(7.8%) 
10/103 
(9.7%) 
5/53 
(9.4%) 
6/55 
(10.9%) 
ASPECTS             
Mean±SD 8.4±2.0 8.3±1.8 9.1±1.0 9.2±0.9 8.7±1.4 8.6±1.4 8.5±1.4 8.4±1.5 7.2±2.1 7.4±2.0 7.4±1.7 7.1±2.1 
Median 
(IQR) 
9 (8-10) 9 (7-10) 9 (9-10) 9 (9-10) 8 (7-9) 9 (8-9) 9 (8-10) 9 (7-10) 8 (6-9) 7 (6-9) 8 (7-9) 7.5 (6-9) 
Ischemic 
core volume 
- mL 
            
Mean±SD 46±44 42±33 20±17 19±19 n/a n/a 11±11 11±16 n/a n/a n/a n/a 
Median 
(IQR) 
32  
(10-69) 
36  
(15-60) 
18  
(4-29) 
12  
(4-32) 
n/a n/a 9.0  
(1-17) 
6.5  
(0-14) 
n/a n/a n/a n/a 
Perfusion 
volume - 
mL 
            
Mean±SD 112±103 141±97 116±48 105±39 n/a n/a 126±63 116±61 7.2±2.1  n/a n/a 
Median 
(IQR) 
97  
(41-181) 
113  
(60-190) 
115  
(72-158) 
106  
(76-137) 
n/a n/a 133  
(79-162) 
125 
(66-149) 
8  
(6-9) 
 n/a n/a 
Clot length 
-mm 
            
Mean±SD n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 15.7±8.7 17.3±11.5 
Median n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 14.1 12.9 (9.4-
(IQR) (10.1-
18.6) 
22.2) 
Collateral 
grade 0 
(worst)/1/2/
3/4 (best) or 
the ESCAPE 
trial collateral 
imaging 
criteria 
9/72/111
/71 
 
 
 
 
17/64/88
/64 
 
 
n/a n/a 145 
adequate 
vs 5 poor 
162 
adequate 
vs 3 poor 
n/a n/a n/a n/a 7/6/10/1
6/6 
7/9/11/1
1/6 
 
 
Table 3. Imaging selection criteria for recent positive acute stroke clinical trials 
Imaging 
selection 
criteria 
MR 
CLEAN 
EXTEND
-IA 
ESCAPE SWIFT 
PRIME 
REVASCAT THERAPY 
Vessel 
occlusion 
ICA, M1, 
M2, A1, 
A2 
occlusion 
ICA, 
M1, 
M2 
ICA, M1 
or 
functional 
M1 
occlusion 
(both/all 
M2 
occlusion) 
ICA, M1 ICA or M1 
occlusion 
ICA, M1 or 
M2 
occlusion 
-Hyperdense 
clot length 
≥8 mm 
-Absence of 
tandem 
extracranial 
steno-
occlusive 
disease 
requiring 
treatment 
prior to 
thrombecto
my 
Small core Not 
required 
RAPID 
perfusion 
infarct 
<70mL 
(relCBF<30
% 
threshold) 
 
ASPECTS 
score 
6-10 
ASPECTS 
score 
6-10 on NCT  
or DWI, 
RAPID 
perfusion infarct 
<50mL 
(relCBF<30% 
threshold) 
 
ASPECTS 
score 
>6 on NCCT, 
ASPECTS 
score 
>5 on DWI 
(NCCT 
ASPECTS >8 
for age 80-85) 
 
Acute 
ischemic 
changes on 
NCCT less 
than one-
third of 
MCA 
territory 
Penumbra Not 
required 
Target 
mismatch: 
RAPID 
perfusion 
ischemic 
core 
mismatch 
ratio>1.2, 
absolute 
mismatch 
>10mL 
(Tmax>6 
sec 
threshold) 
Not required Target 
Mismatch: 
RAPID 
perfusion 
penumbra/infar
ct ratio>1.8, 
penumbra 
absolute volume 
>15mL 
(Tmax>6 sec 
threshold) 
- Tmax>10s 
lesion 
≤100mL 
Not required 
(Clinical/core 
mismatch 
[NIHSS >5]) 
 
Not required 
Collaterals Not 
required 
Not required Adequate 
collateral 
circulation 
defined 
as 
some 
Not required Not required Not required 
filling 
of 
50% 
or 
greater 
of 
the 
ischemic 
territory 
pial 
circulation 
beyond 
occlusion 
on 
CT 
angiograph
y 
(preferably 
multiphase 
CTA) 
 
 
  
Table 4. Imaging modalities obtained at baseline in trial patients (required imaging indicated with an 
asterisk*). The last column indicates the total number of imaging studies available for pooling. 
Modality MR 
CLEA
N 
EXTE
ND-IA 
ESCAP
E 
SWIFT 
PRIME 
REVASC
AT 
THERA
PY 
Total 
Noncontrast 
CT 
(NCCT) 
499/500 
(99.8%)* 
70/70 
(100%)
* 
313/315 
(99.4%)* 
163/195 
(83.6%)* 
206/206 
(100%)* 
108/108 
(100%)* 
1,359 
Perfusion 
CT (PCT) 
333/500 
(66.6%) 
175/500 
(35%) 
available 
70/70 
(100%)
* 
138/315 
(43.8%) 
139/195 
(71.2%) 
64/206 
(31.1%) 
40/108 
(37.0%) 
784 
CT 
Angiography 
(CTA) 
496/500 
(99.2%)* 
70/70 
(100%)
* 
313/315 
(99.4%)* 
159/195 
(81.5%)* 
195/206 
(94.7%)* 
99/108 
(91.7%)* 
1,332 
Diffusion-
Weighted 
MR Imaging 
(DWI) 
19/500 
(3.8%) 
none 2 /315 
(0.006%) 
34/195 
(17.4%)* 
11/206 
(5.3%)* 
3/108 
(2.8%) 
69 
Perfusion-
Weighted 
MR Imaging 
(PWI) 
none none none 34/195 
(17.4%)* 
5/206 
(2.4%) 
1/108 
(0.9%) 
40 
MR 
Angiography 
(MRA) 
2/500 
(0.4%) 
none 2 /315 
(0.006%) 
32/195 
(16.4%)* 
11/206 
(5.3%)* 
2/108 
(1.9%) 
49 
 
 
Table 5. Median times (and interquartile range) for imaging and to treatment in recent positive acute stroke clinical trials, in minutes 
 MR 
CLEAN 
EXTEND-IA ESCAPE SWIFT 
PRIME 
REVASCAT THERAPY 
Multimodal CT 
acquisition time 
n/a 6min28s 
(range: 
3min37s-
9min0sec) 
n/a 8 (4-21) n/a n/a 
PCT post-processing 
time 
n/a 5min20s 
(range: 3-
10min) 
n/a 3.9 (2.2- 5.4) n/a n/a 
Multimodal MR 
acquisition time 
n/a n/a n/a 12 (7-15) n/a n/a 
PWI/DWI post-
processing time 
n/a n/a n/a 2 (1.5-2.7) n/a n/a 
“Door-to-Arterial 
Access” time, 
min 
      
for entire IA cohort n/a 109 
(78-150) 
76 (62-108) 90 (69-120) 109 (85-163) 
 
142 (85-179.5) 
for patients selected 
based on NCCT alone 
n/a n/a n/a n/a n/a 96.5 (83.5-128.5) 
(n=4) 
for patients selected 
based on 
NCCT+CTA 
n/a n/a 76 (62-108) 84 (55-102) 108.0 (85-163) 
 
150.5 (121.5-200.5) 
(n=28) 
for patients selected 
based on 
NCCT+CTA+PCT 
n/a 109 
(78-150) 
n/a 90 (69-112) 103.0 (76-136) 101 (68-160) 
(n=18) 
for patients selected 
based on MRI 
n/a n/a n/a 84 (55-102) 114.0 (94-155) 114.5 (56-173) 
(n=2) 
 
 
Table 6. Research priorities 
Patient selection research priorities 
Standardization of core, mismatch and collaterals definitions 
• Standardizing acceptable methods and imaging parameters within and across modalities 
• Comparability of NCCT ASPECTS, DWI, PCT volume estimates and thresholds, collateral 
scores on multi-phase or single-phase CTA 
• Equivalent definitions and thresholds of mismatch across modalities including coregistration 
methods between core and perfusion imaging in order to precisely measure the mismatch 
volume 
• Acceptable variability, i.e. inter-rater reliability, centralized review versus individual site review 
• Defining futility thresholds 
• Validation of semi-automated methods or fully automated methods of image quantification 
across vendor platforms, devices and modalities 
Final infarct volume research priorities 
• Recommended as outcome measure at Phase II to assess biological effect of therapy 
• Comparison to baseline core volume preferred (volume of change or statistical adjustment) 
• Acceptable variability, i.e. inter-rater reliability, centralized review versus individual site review 
• Optimal timing and modality/sequence 
• Correction for edema, shift due to mass effect, hemorrhagic transformation, atrophy and pre-
existing chronic lesions 
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